Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

Completed · Phase 1 · Has a placebo group

Conditions studied: Chronic Hepatitis C Virus

In brief

The primary objective of the study is to evaluate the safety, tolerability, and antiviral activity of velpatasvir (formerly GS-5816) in HCV treatment naive participants with genotypes 1-6.

Key facts

Study ID

NCT01740791

Run by

Gilead Sciences

People needed

103

Starts

2012-11-06

Expected to finish

2014-01-24

Last updated by the study team

2020-12-16

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• West Coast Clinical Trials, LLC — Costa Mesa, California, United States
• Avail Clinical Research, LLC — DeLand, Florida, United States
• Orlando Clinical Research Center — Orlando, Florida, United States
• Kansas City Gastroenterology and Hepatology — Kansas City, Missouri, United States
• CRI Worldwide, LLC — Marlton, New Jersey, United States
• CRI Worldwide, LLC — Philadelphia, Pennsylvania, United States
• New Orleans Center for Clinical Research-Knoxville — Knoxville, Tennessee, United States
• Alamo Medical Research — San Antonio, Texas, United States
• Charles River Clinical Services Northwest, Inc. — Tacoma, Washington, United States
• Fundacion De Investigacion De Diego — San Juan, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.